View Older Stories
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
Edgewise Therapeutics (EWTX) PT Lowered to $32 at Wedbush
-
Edgewise Therapeutics, Inc. (EWTX) Tops Q3 EPS by 1c
-
Truist Reiterates Buy Rating on Edgewise Therapeutics (EWTX)
-
Goldman Sachs Starts Edgewise Therapeutics (EWTX) at Neutral
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
JPMorgan Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)
-
Edgewise Therapeutics (EWTX) PT Raised to $49 at RBC Capital
-
Raymond James Reiterates Strong Buy Rating on Edgewise Therapeutics (EWTX)
-
Edgewise Therapeutics, Inc. (EWTX) Tops Q2 EPS by 8c
-
Raymond James Starts Edgewise Therapeutics (EWTX) at Strong Buy
-
H.C. Wainwright Starts Edgewise Therapeutics (EWTX) at Buy
-
RBC Capital on Edgewise Therapeutics (EWTX): ' We Would Be Buyers on Weakness'
-
Stifel Reiterates Hold Rating on Edgewise Therapeutics (EWTX)
-
Edgewise Therapeutics Inc. (EWTX) Reports Positive Results on Sevasemten Program
-
Piper Sandler Sees 'Meaningful Upside Opportunities' for Edgewise Therapeutics (EWTX)
-
RBC Capital Reiterates Outperform Rating on Edgewise Therapeutics (EWTX)
-
Edgewise Therapeutics, Inc. (EWTX) Reports In-Line Q1 EPS
-
RBC Capital on Edgewise Therapeutics (EWTX): 'We See Downside Move As A Buying Opportunity'; PT Lowered
-
Edgewise Therapeutics Inc. (EWTX) April 20, April 21, April 22 and May 15 puts active as share price down 21%
-
Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), PT $50
-
Morgan Stanley Reiterates Overweight Rating on Cytokinetics (CYTK)
-
Edgewise Therapeutics Inc. (EWTX) Announces Pricing of $200M Underwritten Offering of Common Stock
-
Edgewise Therapeutics Inc. (EWTX) Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy
-
Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), PT $50
-
Piper Sandler: 'We Remain Bullish on Edgewise Therapeutics (EWTX) and See Compelling Buying Opportunity'
-
Scotiabank Starts Edgewise Therapeutics (EWTX) at Sector Outperform
-
Edgewise Therapeutics, Inc. (EWTX) Reports In-Line Q4 EPS
-
Edgewise Therapeutics Inc. (EWTX) spreader of 3K contracts of March 12.50 puts against 3K contracts of April 22 puts as share price up 4.9%
-
Edgewise Therapeutics (EWTX) PT Raised to $45 at JPMorgan
-
Edgewise Therapeutics (EWTX) Strengthens Leadership Team to Support Late-Stage Clinical Development
-
Stifel Starts Edgewise Therapeutics (EWTX) at Hold
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX) Following Positive Ph2 Data
-
Edgewise Therapeutics Inc. (EWTX) Reports Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten
-
Edgewise Therapeutics Inc. (EWTX) Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
-
Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), 'have reasons to believe that EWTX's study is not the study in question'
-
JPMorgan is out with its 2025 outlook for biotech stocks
-
Edgewise Therapeutics (EWTX) PT Raised to $50 at Truist Securities
-
Evercore ISI Starts Edgewise Therapeutics (EWTX) at Outperform
-
Edgewise Therapeutics, Inc. (EWTX) Tops Q3 EPS by 1c
-
Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)
-
Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)
-
Edgewise Therapeutics (EWTX) PT Raised to $42 at RBC Capital
-
Edgewise Therapeutics (EWTX) PT Raised to $42 at Leerink Partners
-
Edgewise Therapeutics (EWTX) PT Raised to $33 at Truist Securities
-
Edgewise Therapeutics (EWTX) Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy
-
After-hours movers: Intuitive Machines, Casella Waste Systems, Galmed Pharma, Edgewise Therapeutics
-
Edgewise Therapeutics (EWTX) to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy

